Philips enhances neurological diagnosis with the introduction of IntelliSpace Portal 9.0(1)

- Continuously evolving, IntelliSpace Portal 9.0 analysis platform now debuts applications to track and compare brain images(2) to more accurately determine patient progression

- Newest version of advanced visual analysis and quantification platform features machine learning to help streamline physician utilization and enhanced 3D printing options

News provided by

Royal Philips

Nov 28, 2016, 09:00 ET

AMSTERDAM and CHICAGO, Nov. 28, 2016 /PRNewswire/ -- As part of the 2016 Radiological Society of North America Annual Meeting (RSNA), Royal Philips (NYSE: PHG, AEX: PHIA) today announced the introduction of IntelliSpace Portal 9.0, the latest edition of its comprehensive, advanced visual analysis and quantification platform. Featuring a suite of multi-modality functions and expanded neurological tools, IntelliSpace Portal 9.0 helps radiologists detect, diagnose and follow-up on treatment of diseases, while using new machine learning capabilities to support the physician. The solution addresses radiologists' needs for tools to better support the growing group of patients with brain injuries and neurological disorders such as dementia, strokes, amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS).

IntelliSpace Portal 9.0 CT Brain Perfusion. Computed tomography (CT) perfusion imaging is a noninvasive technique often used in the diagnosis of stroke that provides information on delivery of blood or blood flow to the brain. It shows which areas of the brain are supplied or perfused adequately with blood and which areas are in danger due to insufficient perfusion.

IntelliSpace Portal offers Longitudinal Brain Imaging (LoBI1*), an application that has been optimized for the interpretation of brain MRI scan and aims to facilitate the longitudinal evaluation of neurological disorders helping clinicians to monitor disease progression. *Pending 510(k), not available for sale in the United States.

Another feature of IntelliSpace Portal 9.0 is the inclusion of the NeuroQuant(R) application (Cortechs Labs, Inc.), which enables clinicians to objectively quantify brain atrophy.

In addition to enhancements in areas such as CT Brain Perfusion and MR T2 Perfusion IntelliSpace Portal 9.0 will offer Longitudinal Brain Imaging (LoBI)³, an application for neuro reading to support the evaluation of neurological disorders over time so clinicians can monitor disease progression. Another feature is the inclusion of the NeuroQuant® measurement application (CorTech Labs, Inc.) which enables clinicians to quantify brain volume loss.

"As the rates of dementia and neurodegeneration rise, neuroradiologists need advanced tools to help referring physicians treat these challenging cases," said Professor Dr. Leo Wolansky, Acting Chief of Neuroradiology at University Hospitals Cleveland Medical Center in the United States. "IntelliSpace Portal 9.0 offers a comprehensive set of robust tools so neuroradiologists can quantify disease expediently."

With more than 70 applications and enhancements of many of the core applications, IntelliSpace Portal 9.0 is a single platform for visual analysis and quantification that spans clinical domains within radiology, including neurology, oncology, and cardiology. The platform offers improved advanced 3D rendering and refined STL export that enable clinicians to print 3D models with high-levels of detail and resolution, to help understand the anatomy. IntelliSpace Portal 9.0 also includes enhancements to a host of core applications from MR Cardiac Analysis to CT TAVI planning, and System enhancements.

"Radiology has a unique ability to influence and improve outcomes, and intelligent tools enable us to empower radiologists with the right information," said Yair Briman, Senior Vice President and General Manager of Healthcare IT for Philips. "With advances in machine learning, IntelliSpace Portal 9.0 will now be able to continually learn the usage patterns of users to enhance the important daily functions of a radiologist such as pre-preprocessing of images, encouraging faster and more streamlined diagnosis."

IntelliSpace Portal 9.0 offers multimodality clinical applications that can be accessed from any point of the hospital network. The solution can also integrate with typical PACS and hospital information systems to allow for information to be shared broadly, helping drive collaboration across the network. With the enterprise scalability of IntelliSpace Portal 9.0, neurologists can access the power of advanced analysis virtually anywhere across their organization while maintaining consistent applications and user preferences. Some additional highlights of Version 9.0 of the Portal include:

MR Cardiac Enhancements - Facilitates easy visual scoring in various examination contexts. The package enables comprehensive functional volumetric analysis. Enhancements to the package include Whole Heart STL export for 3D printing, and enhanced workflow and batch tools.
CT Spectral Applications - Philips IntelliSpace Portal Spectral Diagnostic suite of clinical applications has been optimized for the viewing and analysis of spectral data sets from the IQon Spectral CT scanner. You can access the application you need when and where you need, virtually anywhere in your enterprise. The tools help you gain a comprehensive overview of each patient, quantify quickly, and diagnose with confidence.

IntelliSpace Portal 9.0 - part of Philips IntelliSpace integrated portfolio of healthcare informatics solutions - will be showcased at booth #6735 at the RSNA Annual Meeting, taking place Nov. 27 - Dec. 2, in Chicago, Ill. Follow @PhilipsLiveFrom or visit www.philips.com/rsna for more information on Philips' presence at #RSNA16 and live updates from the event.

For further information, please contact:

Kathy O'Reilly
Philips Group Communications
Tel.: +1 978-659-2638
E-mail: [email protected]
Twitter: @kathyoreilly

Joost Maltha
Philips Communications Healthcare Informatics, Solutions and Services
Tel.: +31 610-55-8116
E-mail: [email protected]
Twitter: @JoostMaltha

About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips' health technology portfolio generated 2015 sales of EUR 16.8 billion and employs approximately 70,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

¹ Work in Progress. Not yet commercially available.

² Pending 510(k), not available for sale in the United States.

³ Pending 510(k), not available for sale in the United States.

Photo - http://photos.prnewswire.com/prnh/20161123/442566

Photo - http://photos.prnewswire.com/prnh/20161123/442568

Photo - http://photos.prnewswire.com/prnh/20161123/442546

Photo - http://photos.prnewswire.com/prnh/20161123/442567

Logo - http://photos.prnewswire.com/prnh/20140122/NE50581LOGO

SOURCE Royal Philips